John McCarty

Medical Director, BMT and Cellular Therapeutics Laboratory Programs, VCU Massey Cancer Center. Opinions here are my own.

[John McCarty @marrowdoc]

@BldCancerDoc A consummate physician, scientist and leader in our field. Your impact on our field will not soon diminish

[Bruno Paiva @BrunoPaiva_UNAV]

Interesting observation in @NatureCancer: only 60% of hematological patients with #COVID19 receiving anti-CD20 antibody therapy and stem cell transplant developed #SARSCoV2 antibodies. Prior #COVID19 in high risk subgroups does not guarantee immmunizaton!

https://t.co/RuNxqUaiOi

[John McCarty @marrowdoc]

@LemaistreFred @BldCancerDoc @SarahCannonDocs Congratulations!

[Arjun D. Law @Haemophage]

@ASTCT @ASTCT_Journal Platelet refractoriness itself is a marker of severe SOS. We’ve had some transient increments with HLA matched platelets in patients where this preceded diagnosis of SOS but very hard to maintain arbitrary Plt>XX

[ALI ALAHMARI. @Alahmari_MD]

COVID-19 and Hematopoietic Cell Transplant Center-specific survival an... https://t.co/Yjbtg7zo8X

[ALI ALAHMARI. @Alahmari_MD]

Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Effic... https://t.co/SFz10zMFe3

[John McCarty @marrowdoc]

Massey Cancer Center and our Cellular Immunotherapy and Transplant Program treats many historically underserved patients needing transplantation, it was great to participate in this study to expand access to a broader population otherwise not reached with curative intent!

[ALI ALAHMARI. @Alahmari_MD]

Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre study https://t.co/Pi5sIcy9Rs

[Dr. Uma Borate: Professor @beatalleukemia]

Indeed ! Overall survival benefit in AML with various regimes over the last decade. #stillmoreworktodo #clinicaltrials #leusm

[Benlazar S M A @smbenlazar]

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis #mmsm @MyelomaDrKapoor @Rfonsi1
https://t.co/gj7ClwCnzb

[John McCarty @marrowdoc]

@DrMvandenBrink We are pulling for you all!

[John McCarty @marrowdoc]

@Amir_Ahmed_Toor Agree these are the policies we are following according to the Seattle experience. Balancing risk and benefit; individual patient risks also being weighed.

[Naveen Pemmaraju, MD @doctorpemm]

Tweet 2 of 6: #Tweetorial 25-30% of patients with AML will have a FLT3 mutation (including TKD and ITD), so #FLT3 mutations are common; not only common but important for prognostics as FLT3-ITD mutation carries a worse prognosis in patients with diploid cytogenetics
| #leusm

[ASH @ASH_hematology]

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid #leukemia https://t.co/KwlfrRbRBB @BloodAdvances #leusm

[ASTCT @ASTCT]

An updated set of CAR-T resource slides are now available to members and non-members! Everything from the basics of immunology to managing neurotoxicity in CAR-T patients. https://t.co/ugRzd4y9dM

[ALI ALAHMARI. @Alahmari_MD]

Allogeneic Transplantation after Myeloablative Rituximab/BEAM +/- Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-up Results https://t.co/YSD4yy8rhM

[Hemalatha Rangarajan MD https @hmgcoa2]

Nice review on how to chose donors for haploHCT by @Haplo_Doc @TheEBMT consensus recommendations for donor selection in HaploHCT : Check for DSA, choose younger donors , male donor for male recipient, offspring or sibling donor over parent donor
https://t.co/QOtrLRhDTK

[ALI ALAHMARI. @Alahmari_MD]

Standard ATG Dosing Results in Poorer Outcomes in Overexposed Patients after Ex vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation https://t.co/8rgzD3flal

[Philip McCarthy @PLMcCarthyMD]

Transplantation and Myelofibrosis: A Little Medicine and a Little Art https://t.co/T5NOvXVflR

[ALI ALAHMARI. @Alahmari_MD]

Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups https://t.co/i27XXr0zCM